微核检测在肝癌高发现场肝癌防治中的应用研究

MICRONUCLEUS DETERMINATION IN HIGH LIVER CANCER INCIDENCE AREA

为探讨微核试验在原发性肝癌防治中的应用价值,我们应用微核检测技术对1238例不同人群进行了外周血淋巴细胞微核率测定,结果发现下列各人群之间微核率有显着差异:①肝癌(5.80‰)、慢性乙型肝炎(4.34‰)、肝硬化(3.29‰)、肝癌患者一级亲族(2.57‰)与正常人群(0.90‰);②合并HBV感染的肝癌(6.05‰)、慢性肝炎(4.34‰)、肝癌患者一级亲族(2.93‰)、非癌者一级亲族(1.07‰)与健康对照(0.66‰);③肝癌高发家族、慢乙肝、AFP低持阳三组人群与适量服硒后的这三组人群之间。同时发现微核率≥5‰的出现频率肝癌为68.2％,慢乙肝为29.4％,正常人群为0,三组之间有显著差异;且AFP阳性(<50μg/L)的肝癌患者微核率≥5‰的出现频率为66.7％。又发现微核率水平随患者病情进展而升高;对化学药物有效者微核率稳定或下降,骨髓不易受抑制。微核试验作为细胞遗传学方面的一个指标对肝癌的防治研究提供了一项简易快速的方法。

Micronucleus(MN)of lymphocytes of the peripheral blood were measured in 1238 subjects to evuluate the value of micronuclens determination to the prevention and treatment of the primary liver cancer(PLC).There were marked differences in the micronuclens frequency among different groups of people determined:①Those with PLC(5.80‰),chronic hepatitis B(4.34‰),hepatic cirrhosis(3.29‰),first-degree relatives of patients with PLC(2.57‰),and the general population(0.90‰);②PLC patients with HBV infection(6.05‰),individuals with chronic hepatitis B(4.34‰),first-degree relatives of PLC patients(2.93‰).first-degree relatives of cancer-free patients(1.07‰),and healthy controls(0.66‰); And ③Members in families with high incidence of PLC,cases with chronic hepatitis B,individuals with low level AFP,and those having taken Selenium per os.The results also showed that cases with ≥5‰ MN frequency were found to be 68.2% in patients with PLC,29.4% in patients with chronic hepatitis B,and 0% in the general population(P<0.05),and 66.7% in PLC patients with negative AFP(<50μg/L).MN freguency increased with the progress of the disease course.The MN frequency was lower or stable and the bone marrow not easy to be inhibited in those cases who were sensitive to chemical anticarcinogenic drugs. MN test as a cytogenetic marker,provides a simple,fast method for the prevention and treatment of PLC.